Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May-Jun;35(3):243-248.
doi: 10.20524/aog.2022.0703. Epub 2022 Mar 25.

Helicobacter pylori culture: from bench to bedside

Affiliations
Review

Helicobacter pylori culture: from bench to bedside

Angelo Zullo et al. Ann Gastroenterol. 2022 May-Jun.

Abstract

Helicobacter pylori (H. pylori) infection is a widespread infection that causes various gastroduodenal diseases and some extraintestinal disorders. Curing this infection remains challenging for clinicians, mainly because of bacterial resistance towards the few available antibiotics. Therefore, as for other infectious diseases, therapeutic approaches should be opportunely designed using the principles of antimicrobial stewardship. Theoretically, only susceptibility-based antimicrobial therapy should be considered as appropriate for treating this infection. Unfortunately, H. pylori owns some particular characteristics that make the infection slightly peculiar. More specifically, it is "fastidious" about growing in culture, and its isolation is not easily achieved, even in dedicated laboratories that, to make matters worse, are only scantily spread among countries. We examined the pros and cons of bacterial culture for antibiotic susceptibility testing before different therapy lines, and its applicability in the real clinical life.

Keywords: Helicobacter pylori; antibiotic; culture; resistance; susceptibility testing.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None

Figures

Figure 1
Figure 1
A synopsis of available data H. pylori, Helicobacter pylori

References

    1. Mezmale L, Coelho LG, Bordin D, Leja M. Review:Epidemiology of Helicobacter pylori. Helicobacter. 2020;25(Suppl 1):e12734. - PubMed
    1. Caselli M, Zullo A, Maconi G, et al. Working Group of the Cervia II Meeting. “Cervia II Working Group Report 2006”:guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007;39:782–789. - PubMed
    1. Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases:a review. World J Gastroenterol. 2018;24:3204–3221. - PMC - PubMed
    1. Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 2021;22:729–741. - PubMed
    1. De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication:a critical reappraisal of updated guidelines. Ann Gastroenterol. 2017;30:373–379. - PMC - PubMed

LinkOut - more resources